BRPI0919199B8 - suspensão farmacêutica submicrométrica aquosa oftálmica, e seu método de formação - Google Patents
suspensão farmacêutica submicrométrica aquosa oftálmica, e seu método de formaçãoInfo
- Publication number
- BRPI0919199B8 BRPI0919199B8 BRPI0919199A BRPI0919199A BRPI0919199B8 BR PI0919199 B8 BRPI0919199 B8 BR PI0919199B8 BR PI0919199 A BRPI0919199 A BR PI0919199A BR PI0919199 A BRPI0919199 A BR PI0919199A BR PI0919199 B8 BRPI0919199 B8 BR PI0919199B8
- Authority
- BR
- Brazil
- Prior art keywords
- suspension
- submicrometric
- formation
- preparing
- submicron
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
suspensões farmacêuticas submicrométricas estabilizadas e métodos para preparar as mesmas. a presente invenção refere-se a uma suspensão farmacêutica submicrométrica e a um método para preparar a suspensão submicrométrica. a suspensão submicrométrica é útil para administração de agente terapêutico relativamente hidrofóbico e/ou de baixa solubilidade. a suspensão submicrométrica e o método para preparar a suspensão submicrométrica empregam tipicamente um material polimérico que ajuda na prevenção da agregação do agente terapêutico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9828008P | 2008-09-19 | 2008-09-19 | |
US61/098,280 | 2008-09-19 | ||
PCT/US2009/057065 WO2010033528A1 (en) | 2008-09-19 | 2009-09-16 | Stabilized pharmaceutical sub-micron suspensions and methods of forming same |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0919199A2 BRPI0919199A2 (pt) | 2015-12-15 |
BRPI0919199B1 BRPI0919199B1 (pt) | 2020-10-27 |
BRPI0919199B8 true BRPI0919199B8 (pt) | 2021-05-25 |
Family
ID=41353867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0919199A BRPI0919199B8 (pt) | 2008-09-19 | 2009-09-16 | suspensão farmacêutica submicrométrica aquosa oftálmica, e seu método de formação |
Country Status (27)
Country | Link |
---|---|
US (3) | US20100076045A1 (pt) |
EP (2) | EP2425815B1 (pt) |
JP (3) | JP5739809B2 (pt) |
KR (1) | KR101682924B1 (pt) |
CN (2) | CN102176898A (pt) |
AR (2) | AR073597A1 (pt) |
AU (1) | AU2009293400B2 (pt) |
BR (1) | BRPI0919199B8 (pt) |
CA (1) | CA2736106C (pt) |
CL (1) | CL2009001856A1 (pt) |
CY (1) | CY1119740T1 (pt) |
DK (1) | DK2425815T3 (pt) |
ES (2) | ES2592503T3 (pt) |
HK (1) | HK1152258A1 (pt) |
HR (1) | HRP20180050T1 (pt) |
HU (1) | HUE037933T2 (pt) |
LT (1) | LT2425815T (pt) |
MX (1) | MX348204B (pt) |
NO (1) | NO2425815T3 (pt) |
PL (2) | PL2328551T3 (pt) |
PT (2) | PT2328551T (pt) |
RU (1) | RU2521258C2 (pt) |
SI (1) | SI2425815T1 (pt) |
TW (1) | TWI580441B (pt) |
UY (1) | UY32095A (pt) |
WO (1) | WO2010033528A1 (pt) |
ZA (1) | ZA201101398B (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
US20100234469A1 (en) * | 2009-03-12 | 2010-09-16 | Medichem, S.A. | New Crystals Of A Benzoylbenzeneacetamide Derivative |
EP3520749A1 (en) | 2010-10-15 | 2019-08-07 | Clearside Biomedical, Inc. | Device for ocular access |
ES2597038T3 (es) * | 2010-12-06 | 2017-01-13 | Degama Berrier Ltd. | Composición y método para mejorar la estabilidad y extender la vida útil de bacterias probióticas y productos alimenticios de las mismas |
KR102310775B1 (ko) | 2012-05-03 | 2021-10-07 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
NZ741873A (en) * | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
EP2844227B1 (en) | 2012-05-03 | 2020-11-18 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
CN105007898A (zh) * | 2012-12-19 | 2015-10-28 | 卡希夫制药有限责任公司 | 难溶性药物的过饱和的稳定纳米颗粒 |
WO2014127214A1 (en) | 2013-02-15 | 2014-08-21 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
CA2900680C (en) | 2013-02-20 | 2021-08-10 | Kala Pharmaceuticals, Inc. | Quinoline and quinazoline compounds and uses thereof for treating and/or preventing diseases |
AU2014259694B2 (en) | 2013-05-03 | 2018-11-08 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
JP6426194B2 (ja) | 2013-11-01 | 2018-11-21 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物の結晶形態及びその使用 |
WO2016036588A1 (en) * | 2014-09-03 | 2016-03-10 | Merck Sharp & Dohme Corp. | Pharmaceutical suspensions containing etoricoxib |
JP2019514581A (ja) | 2016-05-02 | 2019-06-06 | クリアサイド バイオメディカル,インコーポレイテッド | 眼の薬物送達のためのシステムおよび方法 |
EP3496680A1 (en) | 2016-08-12 | 2019-06-19 | Clearside Biomedical, Inc. | Devices and methods for adjusting the insertion depth of a needle for medicament delivery |
JP2019533641A (ja) | 2016-09-08 | 2019-11-21 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物の結晶形態およびその使用 |
AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
WO2018053318A1 (en) * | 2016-09-16 | 2018-03-22 | Kala Pharmaceuticals, Inc. | Particles, compositions, and methods for ophthalmic and/or other applications |
US20220211618A1 (en) * | 2019-04-16 | 2022-07-07 | Clearside Biomedical, Inc. | Injectable triamcinolone formulations |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5466680A (en) * | 1992-03-26 | 1995-11-14 | Cytologics, Inc. | Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface |
ES2079994B1 (es) * | 1992-10-07 | 1996-08-01 | Cusi Lab | Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica. |
US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
AU5084693A (en) | 1993-08-20 | 1995-03-21 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
US5718919A (en) * | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US6969529B2 (en) * | 2000-09-21 | 2005-11-29 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers |
US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
AU2001259671B2 (en) * | 2000-05-10 | 2004-06-24 | Rtp Pharma Inc. | Media milling |
PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
RU2219910C2 (ru) * | 2002-01-08 | 2003-12-27 | Институт органической и физической химии им. А.Е.Арбузова КНЦ РАН | Ветеринарный имплантируемый препарат иммуностимулирующего действия (варианты) |
US7138468B2 (en) * | 2002-03-27 | 2006-11-21 | University Of Southern Mississippi | Preparation of transition metal nanoparticles and surfaces modified with (CO)polymers synthesized by RAFT |
JP4776229B2 (ja) * | 2002-07-16 | 2011-09-21 | エラン ファーマ インターナショナル,リミティド | 安定なナノ粒子活性物質の液体投与組成物 |
CA2513006A1 (en) * | 2003-01-15 | 2004-08-05 | Dow Global Technologies Inc. | Drug particles obtained by freezing onto a cold surface |
US20040235892A1 (en) * | 2003-05-22 | 2004-11-25 | Yujia Dai | Indazole and benzisoxazole kinase inhibitors |
KR20060095974A (ko) | 2003-09-23 | 2006-09-05 | 알콘, 인코퍼레이티드 | 트리암시놀론 아세토나이드 및 아네코르타브 아세테이트주사용 제제 |
US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
WO2005072710A2 (en) * | 2004-01-28 | 2005-08-11 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
WO2006043172A1 (en) * | 2004-10-19 | 2006-04-27 | Pfizer Inc. | Pharmaceutical compositions and methods for sub-tenon delivery |
WO2006062875A1 (en) * | 2004-12-08 | 2006-06-15 | Merck & Co., Inc. | Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor |
TW200640443A (en) * | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
WO2006110811A1 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Nanoparticulate quinazoline derivative formulations |
CA2603189A1 (en) * | 2005-04-13 | 2006-10-19 | Pfizer Products Inc. | Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles |
US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
JP5112669B2 (ja) * | 2005-09-30 | 2013-01-09 | 富山化学工業株式会社 | 難溶性薬物のナノ微粒子を含有する水性懸濁液剤 |
US20070149480A1 (en) * | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
US20070196350A1 (en) * | 2006-02-22 | 2007-08-23 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
-
2009
- 2009-09-03 TW TW098129672A patent/TWI580441B/zh active
- 2009-09-07 UY UY0001032095A patent/UY32095A/es not_active Application Discontinuation
- 2009-09-15 CL CL2009001856A patent/CL2009001856A1/es unknown
- 2009-09-16 EP EP11191277.0A patent/EP2425815B1/en active Active
- 2009-09-16 CA CA2736106A patent/CA2736106C/en active Active
- 2009-09-16 CN CN2009801371097A patent/CN102176898A/zh active Pending
- 2009-09-16 KR KR1020117008617A patent/KR101682924B1/ko active IP Right Grant
- 2009-09-16 EP EP09792581.2A patent/EP2328551B1/en active Active
- 2009-09-16 JP JP2011527909A patent/JP5739809B2/ja active Active
- 2009-09-16 US US12/560,509 patent/US20100076045A1/en not_active Abandoned
- 2009-09-16 LT LTEP11191277.0T patent/LT2425815T/lt unknown
- 2009-09-16 RU RU2011115211/15A patent/RU2521258C2/ru active
- 2009-09-16 PT PT97925812T patent/PT2328551T/pt unknown
- 2009-09-16 SI SI200931783T patent/SI2425815T1/en unknown
- 2009-09-16 PT PT111912770T patent/PT2425815T/pt unknown
- 2009-09-16 AU AU2009293400A patent/AU2009293400B2/en active Active
- 2009-09-16 PL PL09792581T patent/PL2328551T3/pl unknown
- 2009-09-16 HU HUE11191277A patent/HUE037933T2/hu unknown
- 2009-09-16 WO PCT/US2009/057065 patent/WO2010033528A1/en active Application Filing
- 2009-09-16 DK DK11191277.0T patent/DK2425815T3/da active
- 2009-09-16 BR BRPI0919199A patent/BRPI0919199B8/pt active IP Right Grant
- 2009-09-16 AR ARP090103553A patent/AR073597A1/es not_active Application Discontinuation
- 2009-09-16 CN CN201510086562.7A patent/CN104688682A/zh active Pending
- 2009-09-16 ES ES09792581.2T patent/ES2592503T3/es active Active
- 2009-09-16 NO NO11191277A patent/NO2425815T3/no unknown
- 2009-09-16 PL PL11191277T patent/PL2425815T3/pl unknown
- 2009-09-16 MX MX2011002494A patent/MX348204B/es active IP Right Grant
- 2009-09-16 ES ES11191277.0T patent/ES2657455T3/es active Active
-
2011
- 2011-02-22 ZA ZA2011/01398A patent/ZA201101398B/en unknown
- 2011-06-24 HK HK11106574.8A patent/HK1152258A1/zh unknown
-
2014
- 2014-06-11 US US14/302,122 patent/US20140294970A1/en not_active Abandoned
- 2014-12-11 JP JP2014250576A patent/JP2015052020A/ja not_active Withdrawn
-
2016
- 2016-12-02 JP JP2016234682A patent/JP2017043637A/ja not_active Withdrawn
-
2017
- 2017-04-21 US US15/493,232 patent/US20170216228A1/en not_active Abandoned
-
2018
- 2018-01-05 CY CY20181100015T patent/CY1119740T1/el unknown
- 2018-01-10 HR HRP20180050TT patent/HRP20180050T1/hr unknown
-
2022
- 2022-01-14 AR ARP220100069A patent/AR124648A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0919199B8 (pt) | suspensão farmacêutica submicrométrica aquosa oftálmica, e seu método de formação | |
PH12015502587B1 (en) | Ophthalmic nanoemulsion composition containing cyclosporine and method for preparing same | |
BR112014019667A2 (pt) | formulação de anticorpo abeta | |
BR112015017463A2 (pt) | formulação em pó | |
BR112017025631A2 (pt) | composições oftálmicas aquosas, método de induzir ou aumentar a formação de lágrima, método de formação de aglomerados de ciclosporina a e uso de ciclosporina a | |
CO6280502A2 (es) | Una composicion farmaceutica | |
BRPI0818118B8 (pt) | composição farmacêutica na forma de uma suspensão aquosa estabilizada de carisbamato e seu processo de formação | |
BR112015013278A2 (pt) | composição condicionadora de tecidos | |
BR112014010376A2 (pt) | medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima | |
MX2017008189A (es) | Composicion farmceutica que comprende plasminogeno y usos de este. | |
EA201270050A1 (ru) | Нанодисперсия лекарственного средства и способ ее получения | |
CL2017000120A1 (es) | Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares | |
AR085527A1 (es) | Una composicon farmaceutica para tratar una enfermedad en la cavidad oral que comprende rebamipida | |
HN2011000864A (es) | Particulas inhalables que comprenden tiotropio | |
AR065640A1 (es) | Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la misma | |
NZ607103A (en) | A water-in-oil type emulsion for treating a disease of the eye | |
BR112014016472A2 (pt) | formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo | |
MX2016005764A (es) | Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos. | |
BR112018069901A2 (pt) | aduto de ciclodextrina-panobinostat | |
CL2009002173A1 (es) | Composicion farmaceutica con una liberacion pulsatil de sildenafil que posee fraccion una liberacion inmediata que contiene 5 a 100 mg de sildenafil y una fraccion de liberacion controlada que contiene 25 a 150 mg de sildenafil; proceso para prepararla, util para tratar disfuncion erectil. | |
MX2018005596A (es) | Vacuna para tratamiento y control de patologias infecciosas que usan heparan sulfato (hs) como receptor celular. | |
BR112015003305A2 (pt) | parafuso cirúrgico de elução de fármaco | |
BR112014002293A2 (pt) | processo para a preparação de uma dispersão estável de nanopartículas, dispersão produzida e seu uso | |
BR112014002726A8 (pt) | aglomeração de nanopartículas magnéticas revestidas com alcoxissilano | |
BR112017025527A2 (pt) | preparação farmacêutica líquida, e, método para fabricar uma suspensão de celocoxibe. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: ALCON RESEARCH, LLC (US) |
|
B25A | Requested transfer of rights approved |
Owner name: NOVARTIS AG (CH) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |